Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1101-1108

  Regan, Meredith M ^a,b   Neven, Patrick ^c   Giobbie Hurder, Anita ^a   Goldhirsch, Aron ^d,e   Ejlertsen, Bent ^f   Mauriac, Louis ^g   Forbes, John F ^h   Smith, Ian ^i,j   Láng, István ^k   Wardley, Andrew ^l   Rabaglio, Manuela ^m   Price, Karen N ^a,n   Gelber, Richard D ^a,b,n   Coates, Alan S ^o   Thürlimann, Beat ^p,q  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e Swiss Center for Breast Health   (Switzerland)

^f Rigshospitalet   (Denmark)

^g INSTITUT BERGONIÉ   (France)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^l CHRISTIE HOSPITAL   (United Kingdom)

^m UNIVERSITY OF BERN   (Switzerland)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o UNIVERSITY OF SYDNEY   (Australia)

^p Breast Center   (Switzerland)

^q SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FRACTURE; HEART DISEASE; HOT FLUSH; HUMAN; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MONOTHERAPY; MYALGIA; NIGHT SWEAT; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEQUENTIAL TREATMENT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINAL DRYNESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; AUSTRALIA; BREAST NEOPLASMS; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NEW ZEALAND; NITRILES; NORTH AMERICA; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, STEROID; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SOUTH AFRICA; SOUTH AMERICA; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 81255157751     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70270-4     Document Type: Article

References (23)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
2. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. BIG 1-98 Collaborative Group.
3. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
4. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. BIG 1-98 Collaborative Group.
5. Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
6. Saphner T, Tormey DC, Gray R Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
7. Pritchard KI, Sousa B Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important?. J Clin Oncol 2011, 29:1651-1652.
8. Giobbie-Hurder A, Price KN, Gelber RG Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 2009, 6:272-287.
9. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132.
10. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
11. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Breast Cancer Res 2011, 13:209.
12. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. ATAC Trialists' Group.
13. Finkelstein DM, Schoenfeld DA Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 Trial by using the inverse probability of censoring weighted method. J Clin Oncol 2011, 29:1093-1095.
14. Mauriac L, Keshaviah A, Debled M, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007, 18:859-867.
15. Viale G, Regan MM, Dell'Orto P, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011, 22:2216-2226.
16. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
17. Lazar AA, Cole BF, Bonetti M, Gelber RD Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol 2010, 28:4539-4544.
18. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011, 103:1-11.
19. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
20. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008, 26:1965-1971.
21. Phase III randomized study of continuous letrozole versus intermittent letrozole in postmenopausal women with hormone receptor-positive, node-positive, early-stage breast cancer after completion of 4 to 6 years of prior adjuvant endocrine therapy (accessed May 2, 2011). http://www.cancer.gov/clinicaltrials/IBCSG-35-07.
22. Jordan VC The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death?. J Clin Oncol 2008, 26:3073-3082.
23. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008, 68:4518-4524.